In accordance with original experiments showing constitutive expression of BST2 by cancer cells (143), more recent observations confirmed BST2 overexpression in myelomas, lung cancer, breast cancer, colorectal cancer, and pancreatic cancer (148), which could represent a strong predictor of tumor size, aggressiveness, and poor patient survival (149, 150). Here, BST2 is linked to breast carcinoma.